LL-37 vs Pasireotide
Overview
LL-37 is primarily a immune support peptide, while Pasireotide is used for hormonal.
This page compares LL-37 and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| LL-37 | Pasireotide | |
|---|---|---|
| Category | Immune Support | Hormonal |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 2-5 mg | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | twice weekly | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Antimicrobial activity, immune modulation, wound healing, anti-inflammatory | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Generally safe, minimal side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. LL-37 is categorised under Immune Support, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026. Pasireotide: FDA-approved.
Dosing. LL-37 is typically dosed at 2-5 mg (twice weekly). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking LL-37 and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between LL-37 and Pasireotide?
- LL-37 is primarily a immune support peptide, while Pasireotide is used for hormonal. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Pasireotide is FDA-approved for one or more indications.
- What is LL-37 used for?
- Antimicrobial defense peptide.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take LL-37 and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking LL-37 and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is LL-37 or Pasireotide FDA-approved?
- LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026). Pasireotide is FDA-approved for one or more indications.
Read the full articles
- LL-37 — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references